亚虹医药致力于成为立足中国、并具有国际影响力的新药研发企业。我们专注于开发具有重大治疗意义的抗肿瘤药物。独特的研发策略使得我们的新药研发具有研发周期短、毒副作用低的显著优势。我们的药物APL-1202是目前全球唯一治疗非肌层浸润性膀胱癌的口服药物。
了解更多
Asieris Pharmaceuticals is dedicated to becoming a China-based biotech company with significant global impacts on anti-cancer treatments. Our primary R&D strategy is to leverage the extensive knowledge of "old drugs" for creating breakthrough innovations.
Read More
技术
研发策略
专攻领域
研发产品线
APL-1202

 
 
使用全球领先的药物研发理念

建立独特的药物研发体系:
老药新用(中文)  
  - 安全性好

 - 风险低

 - 研发周期短

  


膀胱癌及其它泌尿生殖系统肿瘤


肿瘤免疫治疗


多药耐药感染
 

  APL-1202
(非肌层浸润性膀胱癌/前列腺癌)

APL-1301
(泌尿生殖系统肿瘤)

APL-1401
(肿瘤免疫治疗)

APL-1501
(多药耐药感染)
中文产品线  



         APL-1202是全球首个非肌层浸润型膀胱癌口服用药,有望极大减轻复发患者接受治疗的痛苦,是目前全球膀胱癌症治疗领域的一项重大突破。

    APL-1202 III期临床招募

    APL-1202 临床治疗非肌层浸润性膀胱癌,属于国家十二五重大新药专项产品。临床治疗经II期临床研究表明其疗效显著、安全性好、且口服给药,颠覆传统的化疗灌注治疗方式,使得癌症治疗不再痛苦。

      我们的III临床研究已经正式启动,如果您感兴趣欢迎您进一步了解相关内容
  - 待满足的市场需求

  - 产品的巨大价值

  - 临床研究进展


Technology
Research strategy
Specialized field
R & D product line
APL-1202

 
 
We have established our unique Research and Development Strategy with below advantages:

老药新用en  
- Superior Human Safety

- Reduced Development Risk

- Shorter R&D Cycle

  


Bladder cancer and
other genitourinary tumors



Tumor immunotherapy



Multi drug resistant infection

 

  APL-1202
(NMIBC/Prostate Cancer)

APL-1301
(Urogenital Cancers)

APL-1401
(Cancer Immunotherapy)

APL-1501
(Multi-drug-Resistance Infection)
product pipeline  



         APL-1202 is the first oral drug in the world for the treatment of non-muscle-invasive bladder cancer (NMIBC), it is recognized as a breakthrough in bladder cancer therapy to relieve the pain of relapsed patients with superior efficacy.

    Patients Recruitment
for APL-1202 Pivotal Trial
 
(Results of a finished Phase II trial showed that) Comparing to current invasive intravesical chemotherapy , APL-1202 showed significant efficacy and superior human safety for NMIBC patients, Its oral administration is convenient and safe, without causing pain or injury to urethra.
 
Currently Our APL-1202 pivotal clinical trial has been initiated and now for patient recruitment. If you are interested and need more information, please click here.
  - Unmet Medical Needs
  - Great Clinical Advantages
  - Clinical Development Update
十二五 英文

合作
我们非常诚挚地寻求与您在多方面合作的机会,亚虹医药将会成为您最好的合作伙伴!
Cooperate
We sincerely welcome the opportunity to partner with you.
公司新闻
-   亚虹医药参展2017 BIO International Convention
-   亚虹医药(展台号4819)期待与您在International BIO相见
-   亚虹医药参加2017 BIO International Convention
媒体报道